• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

TiGenix IPO raises $36m

December 15, 2016 By Sarah Faulkner

TiGenix IPO raises $36mTiGenix (EBR:TIG) said today that it raised $36 million in an initial public offering from the sale of 2.3 million American depository shares, representing 46 million ordinary shares, at $15.50 apiece. The biopharmaceutical company plans to list on the NASDAQ exchange under the “TIG” symbol by Dec. 15. It is listed on the Euronext Brussels under the same symbol.

The IPO includes a 6.9 million share, 30-day over-allotment option for its underwriters. BofA Merrill Lynch and Cowen & Company acted as lead managers on the deal, according to TiGenix. The company anticipates that the offer will close on December 20, 2016.

The Belgium-based company is developing an injectable, adipose-derived stem cell treatment for complex perianal fistulas in Crohn’s disease patients. A 2nd adipose-derived stem cell candidate has undergone a phase I sepsis trial and a phase I/II trial for rheumatoid arthritis.

In July last year, TiGenix acquired Coretherapix and its lead cellular candidate is in a phase II clinical trial for acute myocardial infaction. A different cardiac stem cell candidate from Coretherapix is being developed in a chronic indication.

TiGenix inked a licensing agreement with pharmaceutical giant Takeda (TYO:4502) in July this year, granting Takeda exclusive rights to commercialize TiGenix’s injectable, adipose-derived stem cell treatment for complex perianal fistulas outside of the U.S.

Filed Under: Featured, Initial Public Offering (IPO), Pharmaceuticals, Stem Cells, Wall Street Beat Tagged With: Takeda Pharmaceutical Co, TiGenix

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS